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Introduction
The latest human genome annotation predicts 52 protein
lysine methyltransferases (PKMTs) and 33 protein lysine deme-
thylases (PKDMTs) based on sequence similarities to known
catalytic domains. The number of enzymes involved in the
addition and removal of methyl moieties on lysine residues
suggests that methylation is dynamic and highly regulated,
and numerous undiscovered substrates could exist. Moreover,
several of these enzymes themselves are uncharacterized or
poorly studied. Thus, important questions regarding the bio-
logical relevance and biochemical properties of these enzymes
remain unanswered. In addition, recent reports have linked
PKMTs with the etiology of human diseases, such as cancer,[1]
Huntington’s disease,[2] immunodeficiency syndromes,[3] and
growth defects.[4] Importantly, several PKMTs methylate non-
histone substrates,[5] such as the tumor suppressor p53,[6] the
estrogen receptor ERa,[7] the heterochromatin protein HP1a,[8]
the DNA methyltransferase DNMT1,[9] the ATPase Reptin,[10] and
others. Thus, extensive proteomic profiling of PKMT substrates
will be critical for identifying new nonhistone substrates and
novel histone substrate sites of PKMTs, and for understanding
the biological roles and pathological implications of lysine
methylation.
SETDB1 is a histone H3 lysine 9 methyltransferase[11] that cat-
alyses lysine mono-, di- and trimethylation.[12] Recent work has
identified a critical role for SETDB1 in embryonic stem (ES) cell
differentiation[13] and proviral silencing in ES cells,[14] as well as
a central function in transcriptional silencing as part of a major
repressive complex.[15] Here, we use SETDB1 as a model
enzyme to develop a chemical biology method to identify
novel PKMT substrates.
Lysine methylation events have historically been identified
by candidate approaches, limiting the discovery of unanticipat-
ed but biologically relevant substrates. Therefore, unbiased
methods for labeling and characterizing PKMT substrates
would be of great utility. To address this need, we have devel-
oped a chemical biology approach based on copper-catalyzed
azide-alkyne cycloaddition (CuAAC) chemistry. CuAAC methods
have found broad use in studying many types of cellular pro-
cesses, including such post-translational protein modifications
as glycosylation,[16] lipidation,[17] and acetylation,[18] as well as
DNA replication[19] and RNA dynamics.[20] Because neither al-
kynes nor azides appreciably react with any functional groups
found in natural biomolecules, CuAAC exhibits exquisite specif-
Several protein lysine methyltransferases (PKMTs) modify histo-
nes to regulate chromatin-dependent cellular processes, such
as transcription, DNA replication and DNA damage repair.
PKMTs are likely to have many additional substrates in addition
to histones, but relatively few nonhistone substrates have
been characterized, and the substrate specificity for many
PKMTs has yet to be defined. Thus, new unbiased methods are
needed to find PKMT substrates. Here, we describe a chemical
biology approach for unbiased, proteome-wide identification
of novel PKMT substrates. Our strategy makes use of an
alkyne-bearing S-adenosylmethionine (SAM) analogue, which is
accepted by the PKMT, SETDB1, as a cofactor, resulting in the
enzymatic attachment of a terminal alkyne to its substrate.
Such labeled proteins can then be treated with azide-function-
alized probes to ligate affinity handles or fluorophores to the
PKMT substrates. As a proof-of-concept, we have used SETDB1
to transfer the alkyne moiety from the SAM analogue onto a
recombinant histone H3 substrate. We anticipate that this
chemical method will find broad use in epigenetics to enable
unbiased searches for new PKMT substrates by using recombi-
nant enzymes and unnatural SAM cofactors to label and purify
many substrates simultaneously from complex organelle or cell
extracts.
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icity and very low background reactivity in biological samples,
making it an ideal approach for identification of novel PKMT
substrates. Here, we describe the synthesis of an alkyne-func-
tionalized S-adenosylmethionine (SAM) analogue (Scheme 1A,
1), and report that it is accepted, in vitro, by SETDB1, which
transfers the alkyne onto a recombinant histone H3 substrate.
The resulting alkyne-tagged lysine moiety can then be treated
with azide-bearing reporters, such as a FLAG epitope, by
CuAAC (Scheme 1B). The modified substrates, labeled with re-
combinant PKMTs in such complex mixtures as organelle or
cell extracts, could then be purified by anti-FLAG affinity chro-
matography and identified by mass spectrometry. We expect
that the alkyne-bearing SAM analogue approach will allow the
use of chemical methods to investigate protein methylation in
a variety of experimental contexts and advance the proteomic
identification of methylated proteins.
Results and Discussion
Alkyne–SAM synthesis, purification, and analysis
Previous work has shown that synthetic SAM analogues can
serve as cofactors for other classes of methyltransferases, in-
cluding DNA methyltransferases.[21] Specifically, analogues with
a double or triple bond b to the sulfonium center of the cofac-
tor allow for the efficient enzymatic transfer of extended
groups onto DNA, probably because of the conjugative stabili-
zation of the p orbital of the reactive carbon, which compen-
sates (at least in part) for the steric hindrance imposed by the
larger synthetic cofactor.[21] Based on this work, we reasoned
that 1, a synthetic SAM analogue with a propargyl-substituted
sulfonium functionality, might be accepted by PKMTs. Impor-
tantly, the use of 1 as a cofactor by a PKMT would result in the
transfer of a terminal alkyne moiety onto the PKMT substrate
and allow for selective probe conjugation by CuAAC.
During synthesis and HPLC purification we observed one
major chromatographic peak with associated mass spectra
containing the predicted product mass. NMR analysis indicated
that both diastereomers of 1 were formed, as predicted, and
were present in an approximate 1.67:1 ratio, although initial
attempts to separate the diastereomers chromatographically
have been unsuccessful. Nevertheless, as other unnatural SAM
analogues have been used successfully in biological assays as
mixtures of diastereomers,[22] we evaluated 1 in our PKMT
assays.
Lysine methyltransferase reaction with alkyne–SAM
We tested 1 in an in vitro lysine methylation assay with re-
combinant SETDB1 and recombinant histone H3 tail encom-
passing amino acids 1–42 of H3 fused to GST (GST-tagged
H3tail). Then, following GST purification of GST–H3tail, CuAAC
was performed by using an azide-FLAG probe. As shown in
Figure 1A, SETDB1 efficiently transferred the alkyne group
from 1 to GST–H3tail, as detected by anti-FLAG immunoblot-
ting. Anti-GST immunoblotting confirmed that equivalent
amounts of GST–H3tail were used in this assay (Figure 1A,
lower panel). We then optimized the amount of 1 for the most
effective modification conditions. Using varying amounts of 1,
ranging from 0 to 100 mm, we found that the optimal concen-
tration of 1 for H3 modification by SETDB1 is 50 mm (Fig-
ure 1B). As a loading control, anti-GST immunoblotting was
performed to confirm equal level of substrate in each PKMT
assay reaction. Typically, natural SAM is used at concentrations
in the lower micromolar range (3 to 160 mm) in similar
assays,[23] in agreement with our results with 1. However, we
note that our experiment probably overestimates the concen-
tration of analogue needed for optimal activity, as it is likely
that only one diastereomer is accepted by SETDB1, as with nat-
ural SAM.
Detection and FLAG purification of the substrate
After optimization of PKMT assay conditions with 1, we validat-
ed SETDB1 activity using 50 mm of 1. Lysine methylation re-
Scheme 1. A chemical biology method for labeling lysine methyltransferase
substrates. A) Alkyne–SAM analogue 1. B) PKMT substrate labeling method:
enzymatic transfer by a PKMT of a terminal alkyne from 1 to a protein sub-
strate is followed by CuAAC to ligate an azido-FLAG epitope to the substrate
protein.
Figure 1. Alkyne–SAM assessment in lysine methylation assays. A) SETDB1
was incubated with GST–H3tail and 1 or controls (no cofactor, trace material
from analytical HPLC prep). Following the methyltransferase reaction, the
product was treated with the azide-FLAG and the samples were analyzed by
SDS-PAGE and immunoblotting by using the indicated antibodies. B) Methyl-
transferase reactions were performed as in panel A, but by using 1 in in-
creasing amounts.
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actions were conducted in the absence or presence of either
SETDB1 or 1. Figure 2A shows that the anti-FLAG antibody de-
tects the GST–H3tail solely in the presence of SETDB1 and 1,
demonstrating the transfer of the alkyne moiety onto the sub-
strate. In contrast, SETDB2, a putative PKMT highly homolo-
gous to SETDB1, did not transfer the alkyne moiety from 1;
this suggests that 1 might provide stringent selectivity among
PKMTs (Figure 2B).
Ligation of the FLAG epitope (DYKDDDDK; ~1012 Da)
through CuAAC should alter the migration of the histone sub-
strate relative to the unmodified form. To test this, we used
the anti-FLAG M5 monoclonal antibody, which, due to the rela-
tively high amount of GST–H3tail, also nonspecifically recogniz-
es the unlabeled substrate. Figure 2C shows that the modified
H3 migrates on SDS-PAGE slightly slower than the unmodified
form, as predicted.
To further validate that the FLAG epitope added to the
PKMT substrate by click chemistry is indeed functional, we con-
ducted an immunoprecipitation experiment on SETDB1 GST–
H3tail PKMT reactions in the absence or presence of 1. Fig-
ure 2D shows that recombinant H3 was pulled-down by the
anti-FLAG antibody only when the methylation reaction was
carried out in the presence of 1. Thus, alkyne modified sub-
strates can be purified with antibodies; this suggests that
novel substrates could be purified in this manner and analyzed
by mass spectrometry.
Recently, a chemical biology approach was used to identify
novel lysine acetyltransferase substrates.[18] Yang et al. synthe-
sized a series of acetyl-CoA analogues with alkyne moieties of
variable length in experiments with the histone acetyltransfer-
ase p300.[18] Interestingly, p300 could not transfer the alkyne
moiety from the butynoyl-CoA, but successfully achieved the
transfer from pentynoyl-CoA and, to a certain extent, from hex-
ynoyl-CoA.[18] By analogy, these results suggest that further op-
timization might yield additional future alkyne–SAM analogues
that could be useful either for specific PKMTs or several PKMTs.
Indeed, a very recent report indicates that this is the case for
specific fungal and human PKMTs that use a SAM analogue dis-
tinct from the one we report here.[22b] In addition, Osborne
et al. synthesized an N-mustard SAM derivative, which is trans-
ferred to arginine by the protein arginine methyltransferase,
PRMT1, and proposed that alkyne–SAM could be used for pro-
teomic identification of novel PRMT substrates.[24] Interestingly,
the N-mustard SAM derivative was accepted as a cofactor by
rebeccamycin methyltransferase[25] and DNA methyltransferas-
es[26] to modify their respective substrates. Thus, alkyne–SAM
analogues have the potential to facilitate the proteomic iden-
tification of novel substrates for various families of methyl-
transferases, and possibly other applications, such as methyl-
CpG genomic DNA and mRNA 7-methylguanosine cap tagging.
However, we found that other methyltransferases, including
SET7, SMYD2, PRMT1, CARM1, and PRDM8, -10, and -16, were
unable to accept 1 in in vitro assays, as SETDB1 does (data not
shown). These results suggest that 1 might provide a relatively
specific reagent for the study of SETDB1, and perhaps other
closely related PKMTs, the substrates and functions of which
remain poorly understood.
Conclusions
We note that the work described here provides a “jumping-
off” point for the design and synthesis of future generations of
alkyne- and azide-functionalized SAM analogues with im-
proved properties, including cell permeability and acceptance
by a wider range of PKMTs.
Experimental Section
Alkyne–SAM synthesis and purification: Alkyne–SAM analogue 1
was synthesized essentially according to the method of Dalhoff
et al.[22a] Briefly, S-adenosyl-l-homocysteine (50 mg, 0.13 mmol) was
dissolved in a 1:1 mixture of formic acid and acetic acid (7.5 mL)
on an ice bath. Propargyl bromide (1.2 mL, 7.8 mmol) was added
slowly over 5 min, the reaction was allowed to warm to room tem-
perature and stirred for 4 days. The reaction was then diluted with
water (75 mL) and washed three times with diethyl ether (12.5 mL
each). The aqueous layer was frozen and lyophilized. Lyophilized
material was dissolved in water with TFA (0.1%) and purified by
RP-HPLC by using a Rainin Instruments Dynamax SD-200 system
equipped with a Varian UV/vis detector (model 345) and a Micro-
sorb C18 analytical column (4.6250 mm) with a flow rate of
1 mLmin1 or a preparative column (21.4250 mm) with a flow
rate of 20 mLmin1. HPLC samples were filtered with a Pall Life Sci-
ences Acrodisc CR 13 mm syringe filter equipped with a 0.2 mm
PTFE membrane prior to injection. The product was purified with
an isocratic elution of TFA (0.1%) in water; tR (1)=9.1 min.
1H NMR
(500MHz, D2O): d=8.434 (s, 1H; HA), 8.430 (s, 1H; HB), 8.43–8.41
(m, 1.2H; HA/HB), 6.15 (d, J=3.0 Hz, 1H; HA), 6.12 (d, J=4.0 Hz,
0.6H; HB), 4.88–4.83 (m, 1.4H; HA/HB), 4.64 (dd, J=6.5, 5.5 Hz, 1H;
HA), 4.61 (dd, J=6.0, 5.5 Hz, 0.6H; HB), 4.55 (ddd, J=7.0, 6.0, 4.0 Hz,
1.8H; HA/HB), 4.44 (d, J=2.5 Hz, 0.9H; HB), 4.35 (ddd, J=17.5, 12.5,
2.5 Hz, 2H; HA), 4.09 (dd, J=13.0, 3.0 Hz, 1H; HA), 4.05–4.01 (m,
1.5H; HB), 3.95 (d, J=2.5 Hz, 1H; HA), 3.94 (s, 1H; HA), 3.73–3.58 (m,
Figure 2. Alkyne–SAM transfer onto histone H3 by SETDB1. A) Lysine meth-
ylation assays performed in the absence or presence of 1 and SETDB1.
B) Lysine methylation assays conducted with SETDB2 along with SETDB1 as
a control. C) Lysine methylation assays with 1 analyzed with the M5 anti-
FLAG antibody to show the differential migration of the alkyne-modified
substrate. D) Recombinant histone H3 was immunoprecipitated by using
FLAG M2–agarose after CuAAC.
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3H; HA/HB), 3.24 (t, J=2.5 Hz, 0.4H; HB), 3.12 (t, J=2.5 Hz, 1H; HA),
2.47–2.29 (m, 3.6H; HA/HB) ;
13C NMR (150MHz, D2O, only major
diastereomer, A, reported): d=170.6, 162.9, 162.7, 144.5, 143.2,
117.3, 115.3, 90.0, 81.3, 79.1, 73.2, 73.1, 51.3, 41.8, 36.1, 30.2, 24.5;
ESI-HRMS calcd for C17H23N6O5S
+ : 423.1445 [M]+ , found 423.1447.
Plasmids, cDNA, and antibodies: The histone H3 tail was inserted
in-frame upstream of GST in pGEX (Pharmacia). SETDB1 cDNA was
HA-tagged and inserted in pcDNA3 (Invitrogen). The antibodies
used were anti-GST–HRP (ab3416, Abcam) and anti-FLAG (M2–HRP
and M5–HRP, Sigma).
Recombinant protein purification: Briefly, E. coli strain BL21 DE3
(Stratagene) was transformed with appropriate pGEX plasmids, and
protein expression was induced and purified, as described previ-
ously.[27]
Lysine methylation assay: The KMT assays were essentially per-
formed as described previously,[28] but 1 was used instead of 3H-S-
adenosylmethionine. The reactions were incubated for 2–4 h at
37 8C.
Click reaction: The samples were cleared of 1 by either GST-pull-
down or TCA precipitation. Then, the protein samples were incu-
bated in the presence of sodium ascorbate (1.5 mm), azido-FLAG
(100 mm), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (100 mm),
and CuSO4 (1 mm) at room temperature for 60 min. Reactions were
stopped by addition of Laemmli buffer and analyzed by immuno-
blot.
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